Short report

Brain acetylcholinesterase activity is markedly reduced in dominantly-inherited olivopontocerebellar atrophy

STEPHEN J KISH, LAWRENCE SCHUT, JERRY SIMMONS, JOSEPH GILBERT, LI-JAN CHANG, MICHELLE REBBETOY

From the Human Brain Laboratory, Clarke Institute of Psychiatry, Toronto, Canada; Veterans Administration Hospital, Minneapolis, USA; Victoria Hospital, London, Canada; and University of South Dakota, Sioux Falls, USA

SUMMARY The activity of the acetylcholine catabolising enzyme acetylcholinesterase (AChE) in brain after necropsy of seven patients from one established pedigree with dominantly-inherited olivopontocerebellar atrophy (OPCA), a cerebellar ataxia disorder in which neuropathological changes are assumed to be primarily restricted to cerebellum, lower brain stem and spinal cord. Mean AChE activity was significantly reduced in cerebral (−51% to 65%) and cerebellar (−47%) cortex with a less severe change (−37%) in the hippocampus. The magnitude of the enzyme reduction in cerebral cortex was equal to or greater than that reported in brain of demented Alzheimer’s and Parkinson’s disease patients having loss of AChE-containing nucleus basalis cholinergic neurons. It is concluded that the data provide additional biochemical evidence suggesting a cerebral cortical cholinergic denervation in OPCA.

Much circumstantial evidence suggests that an abnormality of the brain cholinergic system may underlie the cognitive dysfunction of Alzheimer’s disease. In this regard, reduced activity of the cholinergic enzymes choline acetyltransferase (ChAT, E.C. 2.3.1.6.1–3) and acetylcholinesterase (AChE, E.C. 3.1.1.7.1, 4–6) as well as decreased acetylcholine synthesis have been convincingly demonstrated in necropsied and/or biopsied Alzheimer’s disease brain. The results of neuropathological studies in Alzheimer’s disease have provided a morphological explanation for the cholinergic enzyme reduction, namely, a loss of cholinergic neurons emanating from the nucleus basalis—septum-diagonal band of Broca brain region, and terminating in cerebral cortex and limbic subcortical areas. Taken together, the above data provide circumstantial evidence for the cholinergic hypothesis of Alzheimer’s dementia.

Should the cognitive impairment of Alzheimer’s disease dementia be fundamentally due to a brain cholinergic dysfunction a cholinergic reduction in brain of individuals afflicted with non-Alzheimer’s disease neurodegenerative disorders would also be expected to be associated with dementia of Alzheimer’s type. In this regard, Perry and coworkers have recently reported a good correlation between the degree of cognitive dysfunction and extent of cortical ChAT loss in demented Parkinson’s disease patients. Interestingly, however, in this study the severity of the cognitive impairment in the demented Parkinson’s disease patients was, on average, less than that observed in Alzheimer’s disease dementia despite having cortical cholinergic (ChAT and AChE) reduction of similar magnitude. Moreover, the majority of the Parkinson’s disease patients examined did not have any of the cognitive deficits (aphasia, apraxia and agnosia) often associated with Alzheimer’s disease.

We have recently described a cerebral cortical reduction in the activity of the cholinergic marker synthetic enzyme ChAT in the brain of patients from five families afflicted with another non-Alzheimer’s disease neurodegenerative disorder, namely,
Brain acetylcholinesterase activity is markedly reduced in dominantly-inherited olivopontocerebellar atrophy

Parkinson's disease is consistently associated with reduced AChE activity in the terminal regions. Studies of brain AChE in human neurodegenerative conditions may also be of interest in view of the recent evidence that AChE, in addition to its role in acetylcholine catabolism, may have non-cholinergic physiological actions including peptide metabolism and regulation of nigrostriatal neuron activity.

Patients and methods

Brain was obtained at necropsy from seven patients from the Schut kindred. This kindred, which now spans eight generations, was originally described by Gray and Oliver and has been continuously followed. The autosomal dominant locus has been localised to a region 15 centimorgans telomeric of HLA-A on the short arm of chromosome 6. The diagnosis of dominantly-inherited OPCA was made on the basis of clinical signs (limb and gait ataxia, dysarthria and dysphagia), positive family history, and characteristic histological changes in cerebellum, pons and inferior olive. Histological analyses of extracerebellar brain areas conducted on two (only) of the seven OPCA patients revealed an absence of senile plaques, neurofibrillary tangles, or...
significant cell loss in cerebral cortex. Some brain ChAT data on three of the seven cerebral patients have been recently described.\textsuperscript{10} Necropsy brains from nine control subjects without neurological or psychiatric illness were also obtained. Mean ages for the two groups (controls: 39, 4 years; OPCA: 35, 2 years (mean, SE)) did not differ significantly (p > 0.05, Students’ two-tailed t test). The mean interval between death and freezing of the brain at −80°C did not differ significantly for the two groups (controls: 12, 2 hours; OPCA: 9, 2; p > 0.05).

Total AChE was determined by minor modifications of the procedures of Ellman \textit{et al}\textsuperscript{5,25} and Bonham \textit{et al}\textsuperscript{26} employing 1mM acetyl-beta-methylthio-choline as substrate in the presence of 0-01 mM iso-OMPA (Sigma) a specific inhibitor of butyrylcholinesterase. Blanks contained 0-01 mM BW284C51 (Sigma), a specific inhibitor of AChE. ChAT activity was determined by the radiochemical method of Fonnum.\textsuperscript{27}

\textbf{Results}

As shown in the fig the activity of AChE in control brain varied among the different regions examined, with the cerebellar cortex having about ten-fold higher activity as compared with cerebral cortex.

When compared with the controls mean AChE activity in OPCA brain was markedly and statistically significantly reduced in cerebral (−51% to −65%) and cerebellar (−47%) cortex with the hippocampus less severely affected (−37%).

Mean ChAT activity in OPCA was markedly and statistically significantly reduced by 65 to 72% in cerebral cortex with the hippocampus again being less affected (−36%). In cerebellar cortex ChAT levels were nonsignificantly (p > 0.05) elevated by 17%.

\textbf{Discussion}

\textit{Control levels and distribution}

In control human brain regions the mean activity of (total) AChE was similar in magnitude to the levels reported by some groups\textsuperscript{4,16,28} but was about one-tenth the values obtained by Davies.\textsuperscript{1} In agreement with the recent findings of Atack and co-workers\textsuperscript{28} enzyme activity in the cerebellar cortex was about ten-fold higher than cerebral cortex whereas hippocampal values were about twice that of cerebral cortex.

\textit{Cerebellum}

Although the physiological function of acetylcholine in cerebellum is not well understood, an immunohistochemical study in human brain indicates that ChAT, the acetylcholine synthesizing enzyme, appears to be exclusively localised in mossy fibres (possibly originating in the pons) which terminate in the granule cell layer.\textsuperscript{29,30} In contradistinction, the results of histochemical staining studies of the acetylcholine catabolising enzyme AChE demonstrate a more diffuse distribution in both molecular and granule cell layers of the cerebellar cortex with possible localisation to mossy fibres, Golgi cells, and (especially in the human) granule cell terminals.\textsuperscript{29,31,32} Our observation in OPCA of a 45% reduction in AChE in cerebellar cortical homogenates is in agreement with neuropathological findings in a single case with hereditary OPCA demonstrating markedly decreased AChE activity in the molecular layer of cerebellar cortex.\textsuperscript{32} In view of the possible localisation of AChE to granule cell terminals in the molecular layer, our data are also consistent with the histological observations of Landis and co-workers\textsuperscript{33} demonstrating degenerative changes in granule cells in (biopsied) cerebellar cortex of patients from our pedigree.

In contrast to AChE, the activity of ChAT was not significantly different from the controls in OPCA cerebellar cortex. In a previous study of OPCA, cerebellar ChAT levels were reported to be variable with values ranging from 24 to 168% of controls.\textsuperscript{34} Since in OPCA there is marked shrinkage of the cerebellum,\textsuperscript{11,12,24} preservation of afferent terminals to cerebellar cortex should result in artificially above-normal levels of neurotransmitter indices localised to cortical nerve endings when expressed on a concentration basis. Thus, our observation of normal or only slightly elevated ChAT activity in the atrophic cerebellar cortex suggests an actual loss of ChAT—containing (possibly mossy fibre) terminals.

\textit{Extracerebellar brain areas}

To our knowledge this study describes, for the first time, the behaviour of AChE in extracerebellar regions of OPCA brain. Our observation of markedly reduced cortical ChAT activity in a total of seven members of the Schut pedigree confirms and extends our original report (ref. 10, n = 3).

The biochemical demonstration in cerebral cortex and, to a lesser extent, in hippocampus, of reduced activity of both AChE and ChAT strengthens the notion that an actual loss of cholinergic neurones containing these acetylcholine metabolising enzymes is present in OPCA brain. In this regard, in a recent neuropathological study of the basal forebrain cholinergic system in brain of a single patient from a different OPCA family (probable dominant inheritance) a significant (> 60%) neuronal loss was observed in the magnocellular population of the basal nucleus of Meynert,\textsuperscript{35} the brain region which provides the major source of cholinergic innervation ascending to neocortex.\textsuperscript{36} With respect to the present study, in a preliminary (qualitative) histological investigation of the nucleus basalis of patients from the Schut OPCA pedigree we have also observed a marked...
Brain acetylcholinesterase activity is markedly reduced in dominantly-inherited olivopontocerebellar atrophy

reduction in number of AChE staining magnocellular neurons with a less severe involvement of the smaller neurons (Kish and Robitaille, unpublished observations; quantitative morphometric studies in progress).

The magnitude of the cortical AChE reduction in OPCA (−51 to −65%) was equal to or greater than the enzyme deficit reported in brain of demented patients with Alzheimer's disease (−30%,16 −18 to −51%,5 −28 to −60%,6 Parkinson's disease (−30 to −53%,5) or elderly Down's Syndrome (−44%,18).

On average, in the extracerebellar regions the extent of AChE loss paralleled the degree of ChAT reduction with the reduction in AChE being slightly less than the ChAT deficit. This observation is similar to the neurochemical findings in necropsy brain studies of other neurogenerative disorders having brain cholinergic loss, namely Alzheimer's disease5,6 and Parkinson's disease with dementia5 in which the cerebral cortical AChE activity (vs. ChAT) is less extensively reduced. Most likely, this is explained by the localisation of AChE to both cholinergic and non-cholinergic neurons.3,7

Recent biochemical data suggest that the AChE reduction in both Alzheimer's disease and Parkinson's disease cerebral cortex is primarily due to a loss of one particular molecular form (intermediate 10S) of the enzyme which may be localised especially to cholinergic neurons.5,38 In this regard it will be of special interest to determine in future studies whether a selective loss of this predominantly membrane bound38 form of AChE also occurs in OPCA brain.

In conclusion, the present investigation provides additional neurochemical evidence suggestive of a marked cortical cholinergic denervation in patients from one well established hereditary OPCA family. OPCA can now be considered to be one of many neurodegenerative disorders, including Alzheimer's disease,14–6 16 17 Parkinson's disease with dementia5 and elderly Down's Syndrome18 having a brain cholinergic reduction. Neurobehavioural-neuropathological-biochemical correlations in prospective studies of affected patients from this OPCA pedigree will be required to assess the clinical significance of our findings. We further suggest that the results of such investigations of non-Alzheimer's disease neurodegenerative disorders having cortical cholinergic deficiency may actually prove more fruitful in providing a greater understanding of the pathophysiological role of the cholinergic system in dementia than studies devoted solely to Alzheimer's disease.

The authors gratefully acknowledge the financial assistance of the Medical Research Council of Canada (grant # MA-9970) and the National Ataxia Foundation (USA). SK is a Career Scientist of the Ontario Ministry of Health.


References
(olivoponto-cerebellar atrophy). 


24 Currier R. A classification of ataxia. 


26 Bonham JR, Gowenlock AH, Timothy JAD. Acetylcholinesterase and butyrylcholinesterase measurement in the pre-natal detection of neural tube defects and other fetal malformations. 


27 Fonnum F. A rapid radiochemical method for the determination of choline acetyltransferase. 


28 Atack JR, Perry EK, Bonham JR, Candy JM, Perry RH. Molecular forms of acetylcholinesterase and butyrylcholinesterase in the aged human central nervous system. 


29 Kan KSK, Chao LP, Forno LS. Immunohistochemical localisation of choline acetyltransferase in the human cerebellum. 


31 Kasa P, Silver A. The correlation between choline acetyl-

Kish, Schut, Simmons, Gilbert, Chang, Rebbetoy transferase and acetylcholinesterase activity in different areas of the cerebellum of rat and guinea pig. 


33 Landis DMD, Rosenberg RN, Landis SC, Schut L, Nyhan WL. Olivopontocerebellar degeneration, clinical and ultrastructural abnormalities. 


34 Kanazawa I, Kwak S, Sasaki H, et al. Studies on neurotransmitter markers and neuronal cell density in the cerebellar system in olivopontocerebellar atrophy and cortical cerebellar atrophy. 


35 Tagliavini F, Pilleri G. Neuronal loss in the basal nucleus of Meynert in a patient with olivopontocerebellar atrophy. 


36 Mesulam MM, Mufson EJ, Levey AI, Wainer BH. Cholinergic innervation of cortex by the basal forebrain: cytochemistry and cortical connections of the septal area, diagonal band nuclei, nucleus basalis (substantia innominata), and hypothalamus in the rhesus monkey. 


37 Eckenstein J, Sofroniew MV. Identification of central cholinergic neurons containing both choline acetyltransferase and acetylcholinesterase and of central neurons containing only acetylcholinesterase. 


Brain acetylcholinesterase activity is markedly reduced in dominantly-inherited olivopontocerebellar atrophy.

S J Kish, L Schut, J Simmons, J Gilbert, L J Chang and M Rebbetoy

*J Neurol Neurosurg Psychiatry* 1988 51: 544-548
doi: 10.1136/jnnp.51.4.544

Updated information and services can be found at:
http://jnnp.bmj.com/content/51/4/544

**Email alerting service**

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

**Notes**

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/